Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database.

IF 3.2 2区医学 Q1 HEALTH CARE SCIENCES & SERVICES Health and Quality of Life Outcomes Pub Date : 2024-03-13 DOI:10.1186/s12955-024-02227-0

Jyoti Dixit, Nidhi Gupta, Amal Kataki, Partha Roy, Nikita Mehra, Lalit Kumar, Ashish Singh, Pankaj Malhotra, Dharna Gupta, Aarti Goyal, Kavitha Rajsekar, Manjunath Nookala Krishnamurthy, Sudeep Gupta, Shankar Prinja

{"title":"Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database.","authors":"Jyoti Dixit, Nidhi Gupta, Amal Kataki, Partha Roy, Nikita Mehra, Lalit Kumar, Ashish Singh, Pankaj Malhotra, Dharna Gupta, Aarti Goyal, Kavitha Rajsekar, Manjunath Nookala Krishnamurthy, Sudeep Gupta, Shankar Prinja","doi":"10.1186/s12955-024-02227-0","DOIUrl":null,"url":null,"abstract":"Background: Cancer survivors experience a decrement in health-related quality of life (HRQoL) resulting from the disease as well as adverse effects of therapy. We evaluated the HRQoL of cancer patients, stratified by primary cancer site, stage, treatment response and associated adverse events, along with its determinants.Methods: Data were collected from 12,148 patients, sampled from seven purposively chosen leading cancer hospitals in India, to elicit HRQoL using the EuroQol questionnaire comprising of 5-dimensions and 5-levels (EQ-5D-5L). Multiple linear regression was used to determine the association between HRQoL and various socio-demographic as well as clinical characteristics.Results: Majority outpatients (78.4%) and inpatients (81.2%) had solid cancers. The disease was found to be more prevalent among outpatients (37.5%) and inpatients (40.5%) aged 45-60 years and females (49.3-58.3%). Most patients were found to be in stage III (40-40.6%) or stage IV (29.4-37.3%) at the time of recruitment. The mean EQ-5D-5 L utility score was significantly higher among outpatients [0.630 (95% CI: 0.623, 0.637)] as compared to inpatients [0.553 (95% CI: 0.539, 0.567)]. The HRQoL decreased with advancing cancer stage among both inpatients and outpatients, respectively [stage IV: (0.516 & 0.557); stage III (0.609 & 0.689); stage II (0.677 & 0.713); stage I (0.638 & 0.748), p value < 0.001]. The outpatients on hormone therapy (B = 0.076) showed significantly better HRQoL in comparison to patients on chemotherapy. However, palliative care (B=-0.137) and surgery (B=-0.110) were found to be associated with significantly with poorer HRQoL paralleled to chemotherapy. The utility scores among outpatients ranged from 0.305 (bone cancer) to 0.782 (Leukemia). Among hospitalized cases, the utility score was lowest for multiple myeloma (0.255) and highest for testicular cancer (0.771).Conclusion: Older age, lower educational status, chemotherapy, palliative care and surgery, advanced cancer stage and progressive disease were associated with poor HRQoL. Our study findings will be useful in optimising patient care, formulating individualized treatment plan, improving compliance and follow-up.","PeriodicalId":12980,"journal":{"name":"Health and Quality of Life Outcomes","volume":"22 1","pages":"26"},"PeriodicalIF":3.2000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10938809/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health and Quality of Life Outcomes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12955-024-02227-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cancer survivors experience a decrement in health-related quality of life (HRQoL) resulting from the disease as well as adverse effects of therapy. We evaluated the HRQoL of cancer patients, stratified by primary cancer site, stage, treatment response and associated adverse events, along with its determinants.

Methods: Data were collected from 12,148 patients, sampled from seven purposively chosen leading cancer hospitals in India, to elicit HRQoL using the EuroQol questionnaire comprising of 5-dimensions and 5-levels (EQ-5D-5L). Multiple linear regression was used to determine the association between HRQoL and various socio-demographic as well as clinical characteristics.

Results: Majority outpatients (78.4%) and inpatients (81.2%) had solid cancers. The disease was found to be more prevalent among outpatients (37.5%) and inpatients (40.5%) aged 45-60 years and females (49.3-58.3%). Most patients were found to be in stage III (40-40.6%) or stage IV (29.4-37.3%) at the time of recruitment. The mean EQ-5D-5 L utility score was significantly higher among outpatients [0.630 (95% CI: 0.623, 0.637)] as compared to inpatients [0.553 (95% CI: 0.539, 0.567)]. The HRQoL decreased with advancing cancer stage among both inpatients and outpatients, respectively [stage IV: (0.516 & 0.557); stage III (0.609 & 0.689); stage II (0.677 & 0.713); stage I (0.638 & 0.748), p value < 0.001]. The outpatients on hormone therapy (B = 0.076) showed significantly better HRQoL in comparison to patients on chemotherapy. However, palliative care (B=-0.137) and surgery (B=-0.110) were found to be associated with significantly with poorer HRQoL paralleled to chemotherapy. The utility scores among outpatients ranged from 0.305 (bone cancer) to 0.782 (Leukemia). Among hospitalized cases, the utility score was lowest for multiple myeloma (0.255) and highest for testicular cancer (0.771).

Conclusion: Older age, lower educational status, chemotherapy, palliative care and surgery, advanced cancer stage and progressive disease were associated with poor HRQoL. Our study findings will be useful in optimising patient care, formulating individualized treatment plan, improving compliance and follow-up.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症患者的健康相关生活质量及其决定因素：来自印度数据库 12,148 名患者的证据。

背景：癌症幸存者的健康相关生活质量（HRQoL）会因疾病和治疗的不良反应而下降。我们按照癌症的原发部位、分期、治疗反应和相关不良事件对癌症患者的 HRQoL 及其决定因素进行了评估：方法：我们从印度 7 家特意选择的主要癌症医院中收集了 12,148 名患者的数据，使用包括 5 个维度和 5 个级别（EQ-5D-5L）的 EuroQol 问卷调查患者的 HRQoL。采用多元线性回归法确定 HRQoL 与各种社会人口学和临床特征之间的关系：结果：大多数门诊患者（78.4%）和住院患者（81.2%）患有实体瘤。门诊病人（37.5%）和住院病人（40.5%）的发病率较高，年龄在 45-60 岁之间，女性占 49.3-58.3%。大多数患者在招募时处于 III 期（40-40.6%）或 IV 期（29.4-37.3%）。门诊患者的平均 EQ-5D-5 L 实用性得分[0.630（95% CI：0.623，0.637）]明显高于住院患者[0.553（95% CI：0.539，0.567）]。住院患者和门诊患者的 HRQoL 分别随着癌症分期的进展而下降[IV 期：（0.516 和 0.557）；III 期（0.609 和 0.689）；II 期（0.677 和 0.713）；I 期（0.638 和 0.748），P 值结论：年龄较大、教育程度较低、化疗、姑息治疗和手术、癌症晚期和疾病进展与患者的 HRQoL 较差有关。我们的研究结果将有助于优化患者护理、制定个体化治疗方案、改善依从性和随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Health and Quality of Life Outcomes 医学-卫生保健

CiteScore

7.30

自引率

2.80%

发文量

154

审稿时长

3-8 weeks

期刊介绍： Health and Quality of Life Outcomes is an open access, peer-reviewed, journal offering high quality articles, rapid publication and wide diffusion in the public domain. Health and Quality of Life Outcomes considers original manuscripts on the Health-Related Quality of Life (HRQOL) assessment for evaluation of medical and psychosocial interventions. It also considers approaches and studies on psychometric properties of HRQOL and patient reported outcome measures, including cultural validation of instruments if they provide information about the impact of interventions. The journal publishes study protocols and reviews summarising the present state of knowledge concerning a particular aspect of HRQOL and patient reported outcome measures. Reviews should generally follow systematic review methodology. Comments on articles and letters to the editor are welcome.